2024-09-28 - Analysis Report
## Merck & Co Inc (MRK) Stock Analysis Report

**Company Overview:** Merck & Co Inc, also known as MSD outside the United States and Canada, is a global pharmaceutical company that develops, manufactures, and markets a wide range of prescription medicines, vaccines, and animal health products.

**Performance Analysis:**

1. **Performance vs. S&P 500:**
    * MRK's cumulative return is **76.06%**, while the S&P 500 (VOO) has a cumulative return of **134.22%**.
    * This results in a **-58.16%** difference in performance, placing MRK at the **26.17%** percentile compared to its historical performance against the S&P 500.

2. **Recent Price Movement:**
    * Closing Price: **$113.09**
    * 5-day Moving Average: **$115.13**
    * 20-day Moving Average: **$116.45**
    * 60-day Moving Average: **$118.68**

3. **Technical Indicators:**
    * RSI: **31.2** (Below 30, indicating oversold conditions).
    * PPO: **-0.21** (Negative, suggesting potential downward momentum).
    * Delta_Previous_Relative_Divergence: **-11.86** (Negative, indicating short-term downward trend).
    * Expected Return: **0.0%** (Max 5-year expected return based on current investment).

4. **Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-05 | **2.15** | **$16.11 B** |
| 2024-05-03 | **1.88** | **$15.78 B** |
| 2023-11-03 | **1.87** | **$15.96 B** |
| 2023-08-07 | **-2.35** | **$15.04 B** |
| 2024-08-05 | **-2.35** | **$15.04 B** |

* **Recent earnings (2024-08-05):** EPS of **2.15** exceeded analysts' expectations of **1.97**, while revenue of **$16.11 B** was also slightly higher than the estimated **$16.05 B**.

5. **News and Recent Issues:**

* **Recent Market Outlook:** According to FINBOLD, MRK is expected to benefit from the growing demand for its key drugs like Keytruda and its strong R&D pipeline. However, concerns about generic competition and pricing pressure in the pharmaceutical industry are also factors to consider. 
* **Analyst Opinions:** The consensus among analysts surveyed by FINBOLD is "Moderate Buy," with an average price target of **$120.24**, representing a potential upside of **6.3%**.
* **Performance Highlights:**  MRK's recent performance has been volatile, but its strong product portfolio and growth potential are expected to continue to drive future performance.

**Summary:**

MRK's recent performance has lagged behind the S&P 500, and technical indicators suggest a potential short-term downward trend. However, the company's strong recent earnings and positive outlook from analysts point to potential future growth. 

While the pharmaceutical industry faces challenges, MRK's strong product portfolio, R&D pipeline, and potential for growth in key markets make it a stock worth considering for long-term investors. 
